Price movement over the last 24 hours
Archer-Daniels-Midland Co vs McKesson Corporation — how do they compare? Archer-Daniels-Midland Co trades at $79.86 (market cap $37.69B), while McKesson Corporation trades at $817.16 (market cap $94.52B). The key difference: McKesson Corporation is far larger — about 2.5× Archer-Daniels-Midland Co's market cap, and Archer-Daniels-Midland Co pays the higher dividend (2.66%). Which is the better fit depends on your goals.
| ADM | MCK | |
|---|---|---|
Market Cap | $37.69B | $94.52B |
Sector | Consumer Staples | Health |
52-Week High | $84.11 | $995.69 |
52-Week Low | $53.54 | $659.01 |
Enterprise Value | $47.72B | $99.16B |
Dividend Yield | 2.66% | 0.41% |
Signals from Pluang's Aura AI — not financial advice
ADM trades at $78.20, up 1.84% recently, with a bullish technical signal from moving averages and a consensus analyst price target of $78.00. The company has beaten EPS estimates for three consecutive quarters, though revenue has declined from $101.6B in 2022 to $80.3B in 2025. Net cash flow improved to $1.58B in 2025, reversing negative trends from prior years, while the stock shows a P/E of 34.79 and P/S of 0.47, indicating mixed valuation signals.
Outlook is cautiously optimistic with strong cash flow and earnings beats, but risks include declining revenue margins and competitive pressures. The stock offers value characteristics with a low P/S ratio, yet investors face headwinds from narrowing profit margins and global trade volatility in agricultural markets.
McKesson (MCK) trades at $807.33, up 2.67% with strong bullish momentum. The stock shows robust fundamentals with consistent earnings beats and revenue growth from $309B to $359B in 2025. Technical indicators signal bullish momentum with price above key support levels. Recent news highlights McKesson's growth in specialty pharma and oncology services, supported by positive analyst sentiment.
Outlook remains positive with 80% analyst buy ratings and $932.83 consensus price target, offering 15% upside. Risks include policy pressures and margin compression, but diversified portfolio and investment-grade rating provide stability. Earnings momentum and strategic investments position MCK for continued growth in healthcare distribution.
Trailing returns across standard periods
Archer-Daniels Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. Additionally, the company owns an extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients. The company is also a large producer of corn-based sweeteners, starches, and ethanol.
Read more on ADM →McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →